First, PLGA nanoparticles decorated with an anti-HER2 antibody were engineered, showcasing their specific uptake by HER2-positive breast cancer cells (MCF-7) while enabling controlled drug delivery [65]. Here, ERBB2 is linked to breast carcinoma.